328998-25-0
(E)-4-(3-((5-(4-Nitrophenyl)furan-2-yl)methylene)-2-oxo-5-phenyl-2,3-dihydro-1H-pyrrol-1-yl)benzoic
CAS: 328998-25-0
Molecular Formula: C28H18N2O6
328998-25-0 - Names and Identifiers
328998-25-0 - Physico-chemical Properties
| Molecular Formula | C28H18N2O6 |
| Molar Mass | 478.45 |
| Solubility | DMSO : 18.33 mg/mL (38.31 mM; Need ultrasonic) |
| Appearance | powder |
| Color | brown to dark brown |
| Storage Condition | 2-8°C |
| Use | 4E1RCat is a cap-dependent translation inhibitor capable of inhibiting the eIF4E:eIF4GI interaction with an IC50 value of about 4 μM. |
| In vitro study | 4E1RCat is an inhibitor of eIF4E:eIF4GI interaction, with an IC 50 an of ∼4 μM. 4E1RCat binding to eIF4E also interferes with eIF4G and 4E-BP binding. 4E1RCat inhibits ribosome recruitment to mRNA in a cap-dependent manner. 4E1RCat blocks the capped mRNA translation, and the translation is activated by CDK1/CYCB1. Nearly all new protein synthesis in both mitosis and interphase is cap-dependent and -sensitive to 4E1RCat treatment, in HeLa and U2OS cells. |
| In vivo study | 4E1RCat (15 mg/kg, i.p.) affacts chemosensitivity of Pten +/- Eμ-Myc tumors in mice. 4E1RCat (15 mg/kg, i.p.) sensitizes Pten +/- Eμ-Myc and Tsc2 +/- Eμ-Myc lymphomas to the cytotoxic effects of doxorubicin (Dxr), and 4E1RCat targets translation in mice. |
328998-25-0 - Risk and Safety
| WGK Germany | 3 |
328998-25-0 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.09 ml | 10.45 ml | 20.901 ml |
| 5 mM | 0.418 ml | 2.09 ml | 4.18 ml |
| 10 mM | 0.209 ml | 1.045 ml | 2.09 ml |
| 5 mM | 0.042 ml | 0.209 ml | 0.418 ml |
Last Update：2024-01-02 23:10:35
328998-25-0 - Reference Information
| biological activity | 4E1RCat is a dual inhibitor of eIF4E: eIF44 G and eIF4E:4E-BP1 interaction, with IC50 of 3.2 μM to inhibit eIF44E. |
| target | IC50: 4 μ m (eIF4E/eIF4G) |
| in vitro study | 4E1RCat is an inhibitor of eIF4E:eIF4GI interaction, with an IC 50 an of 4 μ M. 4E1RCat binding to eIF4E also interferes with eIF4G and 4E-BP binding. 4E1RCat inhibits ribosome recruitment to mRNA in a cap-dependent manner.4E1RCat blocks the capped mRNA translation, and the translation is activated by CDK1/CYCB1. Nearly all new protein synthesis in both mitosis and interphase is cap-dependent and -sensitive to 4E1RCat treatment, in HeLa and U2OS cells. |
| in vivo study | 4 E1RCat (15 mg/kg, I. p.) affacts chemosensitivity of Pten /- Eμ-Myc Tumors in MICE. 4 E1RCat (15 mg/kg, I. p.) sensitizes Pten /- Eμ-Myc and Tsc2 /- Eμ-Myc lymphomas to the cytotoxic effects of doxorubicin (Dxr), and 4E1RCat targets translation in mice. |
Last Update：2024-04-09 21:04:16
Supplier List
Spot supply
Product Name: (E)-4-(3-((5-(4-Nitrophenyl)furan-2-yl)methylene)-2-oxo-5-phenyl-2,3-dihydro-1H-pyrrol-1-yl)benzoic Visit Supplier Webpage Request for quotationCAS: 328998-25-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: (E)-4-(3-((5-(4-Nitrophenyl)furan-2-yl)methylene)-2-oxo-5-phenyl-2,3-dihydro-1H-pyrrol-1-yl)benzoic Visit Supplier Webpage Request for quotationCAS: 328998-25-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History